We report two cases of Ross River virus (RRV) infection in Dutch travellers who visited Australia during February to April 2015. These cases coincided with the largest recorded outbreak of RRV disease in Australia since 1996. This report serves to create awareness among physicians to consider travel-related RRV disease in differential diagnosis of patients with fever, arthralgia and/or rash returning from the South Pacific area, and to promote awareness among professionals advising travellers to this region.

Case presentation

Case 1
A woman in her early 50s with a history of polymyalgia rheumatica visited the outpatient department of a hospital in Rotterdam because of persistent joint pains after travel to Australia. She had stayed in Australia from 30 January until 5 March, where she mainly stayed in the surroundings of Perth. From 7 February, she stayed in Cairns for six days. She recalled having had multiple mosquito bites during her stay in Cairns. Seven days after her return to Perth (on 20 February), she developed fever, fatigue, frontal headache, muscle aches and arthralgia of her hands, wrists, feet and ankles. In addition, she noticed an itchy papular rash on her face, neck and trunk. She was treated with prednisone by a local general practitioner for a presumed recurrence of her polymyalgia, pending the results of serological investigations. Serology for RRV was IgM positive, therefore treatment with prednisone was discontinued.

Two months after returning to the Netherlands, she still experienced debilitating arthralgia and an unsteady gait, frequently necessitating the use of a walking aid. In addition, she reported a subfebrile temperature and sweating. On physical examination, no abnormalities were seen. She had a normal body temperature of 36.9 °C and her joints did not show any sign of arthritis. Laboratory investigation revealed an elevated erythrocyte sedimentation rate (ESR) of 32 mm/hr, a normal leukocyte count of 6.6 x 10^9/L, no abnormalities in the differential morphology of the leukocytes and a C-reactive protein (CRP) level of 6 mg/L (norm: <10 mg/L). Serological testing for RRV on convalescent serum (taken 7 April) showed the presence of IgM and seroconversion for IgG antibodies specific for RRV (Table). RRV aetiology was further confirmed by comparative indirect immunofluorescence assay (IIFA) for RRV, Barmah Forest virus (BFV), chikungunya virus (CHIKV) and Sindbis virus (SINV), and virus neutralization (Table). BFV, CHIKV and SINV are alphaviruses causing symptoms comparable to those caused by RRV, which are endemic to the region.

Case 2
A woman in her late 60s visited her general practitioner on 11 May 2015 with complaints of fatigue, myalgia, arthralgia and a maculopapular rash but no fever. The patient had visited Australia from 29 March to 9 May 2015, where she stayed in New South Wales (in Sydney, Armidale and a mangrove forest near Coff Harbour). She recalled having been bitten by mosquitoes during a trip on 14 April. The first symptoms of wrist pains appeared around 21 April, followed by a rash a few days later. The patient visited a local physician on 27 April and treatment with meloxicam was initiated. Laboratory investigation revealed a normal erythrocyte sedimentation rate of 5 mm/hr. Diagnostics for RRV,
Upon the patient’s return to the Netherlands, the rash reappeared (Figure) and the joint pains in her hands and knees increased. Treatment with naproxen was started. Serology for *Borrelia burgdorferi* showed IgM but no IgG; however, this diagnosis remained inconclusive as it was not confirmed by analysis of a second serum sample. Serological testing for RRV and BFV on a convalescent serum taken on 20 May showed the presence of IgM and IgG antibodies specific for RRV (Table). A second serum sample taken on 24 June showed decreasing IgM and increasing IgG titres. RRV aetiology was further confirmed by comparative IIFA for RRV, BFV, CHIKV and SINV, and by virus neutralisation (Table).

**Background**

RRV, an alphavirus transmitted by mosquitoes, is endemic in tropical and subtropical Australia (Northern Territory and Queensland) with year-round notification of human cases, while in temperate Australia (New South Wales and Victoria) human cases occur seasonally and in epidemics [3,6]. According to the Australian Department of Health, by 23 June 2015, a total of 7,552 RRV disease cases had been reported this year, which is the largest number of annual reported cases since 1996 [7]. Most cases up to 23 June were reported in Queensland (n = 5,075) and New-South Wales (n = 1,292) and peak incidences were in February to April.

The incubation period for RRV disease (also called epidemic polyarthritis) is typically 7–9 days, ranging from 3 to 21 days [1]. In 55–75% of infections, the individuals are asymptomatic. Symptomatic disease typically includes arthralgia, myalgia and fatigue.

Low-grade fever (37.5–38.5 °C) and maculopapular rash on the torso and limbs (sometimes palms, soles and face) occur in 50–60% of clinical cases [1]. Joint pain, stiffness and swelling are usually symmetrical, affecting wrists, hands, fingers, ankles and knees. Additional manifestations may include headache, diarrhoea and nausea. Symptoms most often resolve.
within 3–6 months; permanent sequelae have not been described.

Treatment of symptomatic cases is supportive. Analgesics and nonsteroidal anti-inflammatory drugs may be helpful in the treatment of arthritis and arthralgia. No vaccine is available [1,3].

Laboratory findings are non-specific. Leukocyte counts and CRP levels are usually normal, ESR elevated. Diagnostics are most often based on serology as the viraemic stage is very short (typically fewer than seven days post symptom onset for alphaviruses) and molecular diagnostics are not considered useful on samples taken more than a week after symptom onset. Serology is complicated by putative cross-reactivity with other alphaviruses, especially CHIKV, which belongs to the same serogroup [1,3,8].

**Discussion**

Diagnosis of RRV disease in travellers returning to Europe is very rare [8-11]. A history of mosquito bites and stay in RRV-affected areas are epidemiological parameters supportive of a confirmative diagnosis based on RRV IgM and IgG responses. Based on these criteria, only three cases of RRV disease have been confirmed between 1 January 2009 and 30 June 2015 in the Netherlands, including the two cases in 2015 reported here, who had additional confirmation by gold-standard serology (virus neutralisation). In this period, a total of 56 diagnostic requests for RRV were submitted to the Dutch national arbovirus reference centre in Rotterdam. Of these, 20 requests indicated the travel destination as Australia and/or Asia-Pacific; for 30 requests, the travel destination was unknown. Although local circulation of RRV is unknown, travel to Indonesia, Thailand, Malaysia and the Philippines triggered diagnostic requests as well. Febrile disease and/or arthralgia were the most common symptoms (in 21 of 35 diagnostic requests with clinical data), leading to RRV disease being considered.

The cases presented here highlight the importance of considering RRV in differential diagnosis for travellers presenting with acute arthritis returning from Australia and the Asia-Pacific region. The two cases we describe were related to travel to risk areas in Australia in February/March and March–May 2015. Other arboviruses circulating in Australia and causing polyarthritis that should be included in differential diagnosis are the alphaviruses BFV and SINV, and the flaviviruses West Nile virus (Kunjin virus, KUNV) and Kokobera virus (KOKV). Depending on other travel destinations in the Asia-Pacific region, chikungunya virus, dengue virus and Zika virus should be considered as well [3,12]. The annual incidence of RRV disease in Australia ranges from 2,000 to 8,000 cases; for BFV disease, from 500 to 2,800. Human cases of KUNV or KOKV disease are rare, while the occurrence of human infections with the Oceania lineage of SINV is under debate [3,12].

Although RRV-viraemic travellers have been linked to the spread and epidemics with RRV in the Asia-Pacific region, it is highly unlikely that return of viraemic travellers to Europe will result in autochthonous transmission. As the duration of viraemia is short, the likelihood that a traveller will be viraemic on their return is small. More importantly, the three main vectors for RRV transmission based on field isolations and competence studies are either strictly confined to Australia (Ae. vigilax and Ae. comptortyhynchos, both invasive but not established in New Zealand) or the Asia-Pacific region (C. annunlifrosti) [1].

This report underlines the need for awareness of RRV-related risks among physicians, professionals advising travellers and travellers themselves. Australia is a popular travel destination for Europeans, especially for German, British and French tourists [13]. The number of leisure travellers from the Netherlands to Australia and/or New Zealand has been stable during 2002 to 2011, averaging to 52,000 travellers per year [14]. In January to March 2015, a total of 459,700 Europeans, including 12,600 from the Netherlands, had travelled to Australia [13]. Infection is preventable using common mosquito-prevention measures such as wearing long trousers, long sleeves, light-coloured clothes and insect repellents.

**Acknowledgements**

Tessa Bal, Sandra Scherbeijn, Sabine Köhler, Birgit Hüsing, Insa Bonow, Alexandra Bialonski, Mathis Petersen are acknowledged for excellent technical assistance. Annemiek van der Eijk for discussions and critical reading of the manuscript.

**Conflict of interest**

None declared.

**Authors’ contributions**


**References**


